Show results for
Refine by
Pre Clinical Study Equipment Supplied In Germany
11 equipment items found
Manufactured by:InVivo BioTech Services GmbH a BRUKER Company based inHennigsdorf, GERMANY
Transient gene expression in mammalian cells provides reasonable amounts of recombinant proteins and antibodies which is sufficient for most applications. Nevertheless, when it comes to bulk productions for in vitro diagnostics or pre-clinical studies for biopharmaceutical development, the required amount of biological material often exceeds the ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-Immune are cells that have been induced with tumor necrosis factor alpha (TNF-a) and interferon-gamma (IFN-g), to transiently alter their secretion profile. The product has been evaluated in pre-clinical studies and a peer-reviewed article in the journal Scientific Reports, from Nature, was published which examined the effect of the cells in ...
Manufactured by:Medprin Biotech GmbH based inFrankfurt, GERMANY
100% absorbable within 7-14 days. Hemostasis in capillary, venous as well as small artery bleeding. StypCel™ works when ligation or other conventional methods are impracticable or ...
Manufactured by:ZIND Verfahrenstechnik based inMainz, GERMANY
At pilot stage, the primary membrane candidate has been chosen, as process parameters. Typically at this stage, the production method is being verified and production materials produced for toxicology or pre-clinical trials and predictable scalability is imperative. In order to facilitate the manufacturing life cycle of a successful therapeutic candidate, cGMP manufacturing needs to begin at ...
Manufactured by:Sequana Medical NV based inSint-Denijs Westrem, BELGIUM
Direct Sodium Removal (DSR®) therapy is Sequana Medical’s novel and proprietary approach under development for the management of fluid overload due to heart failure. The sodium concentration in patients with fluid overload is in balance but there is too much sodium and too much fluid in the body. Sequana Medical’s approach is to remove excess sodium in patients with ...
Manufactured by:PhenoSys GmbH based inBerlin, GERMANY
The optomotor response (OMR) is a reflex used to assess visual function. The PhenoSys qOMR (quantitative optomotor response) is a unique system that automatically measures the OMR with minimal experimenter effort. It uses a virtual stimulation cylinder that continuously aligns with the animal´s head position. Based on real-time head tracking, quantitative OMR measurements run fully ...
Manufactured by:Camurus AB based inLund, SWEDEN
FluidCrysta nanoparticles can resolve bioavailability issues for water and lipid-soluble pharmaceuticals or biodegradation-sensitive drugs, such as peptides and proteins. FluidCrystal nanoparticles are usually water-based and comprise a stable emulsion of nanoparticles with a liquid crystalline structure. Investigational medicinal products based on this technology are administered either ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. The compound has demonstrated a wide therapeutic window, with activity seen at a 48 mg dose in a lymphoma study and with a maximum ...
Manufactured by:advanceCOR GmbH based inPlanegg, GERMANY
Our GPVI-inhibiting antibodies follow a completely new mode of action. They prevent activation of blood platelets and are thus supposed to protect against heart attacks and strokes. They have proven their high specificity and effectiveness in animal models without increased bleeding ...
Manufactured by:advanceCOR GmbH based inPlanegg, GERMANY
This is a new type of drug for the treatment of thyroid diseases and the complications they cause in the heart and ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is currently in a Phase I clinical trial to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and in development to ...